药物开发商Septerna（股票代码：SEPN）今日盘中大涨5.25%，引发市场关注。这一显著涨幅主要归因于富国银行对该公司股票评级的上调。
据悉，富国银行将Septerna的股票评级从"等权重"上调至"增持"，同时将目标价从18美元大幅上调至28美元。分析师表示，他们对Septerna的SEP-479（一种口服PTH1R）的安全性以及与该公司之前项目的差异化表示有信心。富国银行特别指出，Septerna在犬科猴上进行的研究有望证明SEP-479不存在此前药物SEP-786所显示的胆红素水平升高问题。
此外，富国银行还强调，Septerna的SEP-631化合物的第一阶段研究结果将成为近期的重要催化剂。分析师预计，公司的SEP-479化合物有望于2026年底上市。这些积极因素综合推动了投资者对Septerna未来发展前景的信心，从而带动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.